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Abstract
Alzheimer´s disease is the most prominent type of dementia and currently no causative
treatment is available. According to recent studies, oligomeric species of the amyloid beta
(Aβ) peptide appear to be the most toxic Aβ assemblies. Aβmonomers, however, may be
not toxic per se and may even have a neuroprotective role. Here we describe a competitive
mirror image phage display procedure that allowed us to identify preferentially Aβ1–42 mono-
mer binding and thereby stabilizing peptides, which destabilize and thereby eliminate toxic
oligomer species. One of the peptides, called Mosd1 (monomer specific d-peptide 1), was
characterized in more detail. Mosd1 abolished oligomers from a mixture of Aβ1–42 species,
reduced Aβ1–42 toxicity in cell culture, and restored the physiological phenotype in neuronal
cells stably transfected with the gene coding for human amyloid precursor protein.
Introduction
Dementia counts for more than 30 million patients worldwide. Alzheimer´s disease (AD) is the
most frequent type of dementia and therefore contributes largely to this number [1, 2]. Because
age is the most important risk factor for AD, the number of AD patients is expected to increase
further.
AD is a progressive type of dementia with symptoms like memory loss, apathy, depression,
anxiety and behavioral changes as well as neuropathological hallmarks including inflamma-
tion, neuronal cell death and loss of brain mass [2–6]. To date, AD can only be treated pallia-
tively and symptomatically, although with only limited success. Throughout our life time, Aβ is
constantly produced from the amyloid precursor protein (APP) by β- and γ-secretases [7, 8].
Currently, soluble Aβ oligomers are assumed to be the major toxic species in AD [9–11]. Aβ
oligomers were shown to account already at nanomolar concentrations for neuronal atrophy,
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induction of synaptic dysfunction, formation of pores and thereby disturbance of cellular ion
homeostasis and inhibition of long-term potentiation, altogether leading to impaired neuronal
function, reduced cognition and a decline in memory [12–16]. The conversion between the dif-
ferent Aβ assembly states is dynamic and reversible [13, 14, 17–22]. Recent research gave rise
to the fact that AD might be a prion-like disease with misfolded Aβmolecules acting as nucle-
ation seeds and initiating aggregate formation by recruiting additional unfolded or oligomeric
Aβ peptides and thereby accelerating amyloid growth [23, 24].
From the current point of view, elimination of Aβ oligomers may be the most promising
therapeutic intervention to AD. Our approach was to identify therapeutically interesting com-
pounds by selection of ligands, which modulate the dynamic equilibrium of Aβ1–42 species
towards decomposition of toxic oligomers by binding of the ligand to monomeric Aβ and stabi-
lizing it within the equilibrium and thereby shifting the equilibrium away from Aβ oligomers.
Phage display selection is suitable to identify small peptide ligand that bind to any target, for
example, Aβ. The variation of phage display using the exact mirror image of the original target
is called mirror image phage display. This method allows the identification of peptides that
consist solely of D-enantiomeric amino acid residues [25, 26]. Such D-peptides are more prote-
ase-resistant than peptides consisting of L-enantiomeric amino acid residues and have a pro-
longed half-life in the body [27–30]. Additionally, D-peptides are assumed to show lower
immunogenicity even though immunogenicity levels may depend on the dose and frequency
of administration [27–29, 31, 32].
Previously, we have shown that the D-peptide D3, which was derived from a mirror image
phage display selection, is able to reduce the amyloid plaque load in transgenic mice, improve
cognition and reduce inflammation after oral application [33, 34]. This has proven the suitabil-
ity of mirror image phage display to identify highly active compounds that are stable enough
for oral administration.
Here, we set out to repeat this successful strategy, but with an important modification to
yield small, D-enantiomeric peptides that show increased specificity for Aβmonomers in order
to stabilize them. Based on a previously described combination of selection and counterselec-
tion [35] we used D-enantiomeric Aβ1–42 monomers as bait and added Aβ1–42 oligomers and
fibrils as counterselective agents to achieve our goal.
Materials and Methods
Peptides
Mosd1 (ysyltsyhmwvr-NH2, all amino acids are D-enantiomers) with> 98% purity was pur-
chased from peptides & elephants (Potsdam, Germany). N-terminally biotinylated and non-
biotinylated D-enantiomeric Aβ1–42 was purchased from JPT (Berlin, Germany), N-terminal
biotinylated L-enantiomeric Aβ1–42 was purchased from AnaSpec (Fremont, CA, USA) and L-
enantiomeric Aβ1–42 was acquired from Bachem (Bubendorf, Switzerland).
Preparation of seedless Aβ1–42 stock solutions
Generally, all Aβ1–42 preparations were handled in siliconized reaction tubes with protein low
binding features (Protein LoBind tubes, Eppendorf AG, Hamburg, Germany) and prepared as
seedless stock solutions as follows. Aβ1–42 was dissolved in PTFE-filtered 1,1,1,3,3,3-hexafluor-
2-propanol (HFIP) and incubated at room temperature (RT) overnight. The HFIP was evapo-
rated in a vacuum centrifuge at RT and additionally overnight in the open reaction tube cov-
ered with a lint-free wipe. The Aβ1–42 film was dissolved in filtered HFIP to 1 mM, aliquoted,
sealed with parafilm and stored at -20°C. Prior to use, HFIP was evaporated.
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Separation of Aβ1–42 species via size exclusion chromatography (SEC)
In order to obtain monomeric and oligomeric Aβ1–42 fractions, size exclusion gel filtration
chromatography was executed following an optimized protocol of Johansson et al. [36]. Seed-
less Aβ1–42 in HFIP was dried in a vacuum centrifuge and solved in elution buffer (50 mM
sodium phosphate, 150 mMNaCl, pH 7.4) to a concentration of 250 μM. After one minute
vortexing, the sample was sonicated for one minute and centrifuged for 60 seconds at 16,000 x
g to precipitate eventually undissolved remains. The supernatant was transferred in a syringe
to a Superdex 75 10/300 GL column connected to an ÄKTA purifier FPLC chromatography
system (both GE Healthcare Europe GmbH, Freiburg, Germany). Size exclusion was executed
at a flow rate of 0.6 ml per minute and detection took place at 214 nm. The desired fractions
were collected and pooled. Aβ1–42 oligomers eluted at about 8 ml and Aβ1–42 monomers at
approximately 14 ml.
Preparation of Aβ1–42 samples with a broad range of different sized
species
In order to gain a solution of Aβ1–42 which resembles several toxic and nontoxic Aβ species
over a broad size range, 80 μM seedless Aβ1–42 was incubated in 10 mM sodium phosphate
buffer (pH 7.4) for 4.5 hours at RT and shaking at 600 rpm.
Preparation of Aβ1–42 fibrils
In order to gain Aβ1–42 fibrils, seedless Aβ1–42 was incubated at 80 μM in 10 mM sodium phos-
phate buffer (pH 7.4) at RT for at least 24 hours with shaking at 600 rpm. To separate the fibrils
from other species, the sample was loaded onto an iodixanol density gradient as described
below. Fractions containing fibrils and high molecular weight (HMW) aggregates (fractions
12–14) were used for further experiments.
Density gradient centrifugation (DGC)
In order to separate differently sized Aβ1–42 assemblies, 100 μl of the sample were added on the
top of a discontinuous gradient of iodixanol (OptiPrep, AXIS-SHIELD, Oslo, Norway). The
gradient was prepared by layering 260 μl of 50% iodixanol at the bottom of a 11 x 34 mm poly-
allomer centrifuge tube, overlaid by 260 μl of 40%, 260 μl of 30%, 780 μl of 20%, 260 μl of 10%
and 100 μl of 5% iodixanol. The samples were spun at 260,000 x g for three hours at 4°C in an
Optima MAX-XP ultracentrifuge with a TLS-55 rotor (both Beckman Instruments, Brea,
USA). After centrifugation, 14 fractions of 140 μl each were harvested with a pipette from top
to bottom.
Competitive mirror image phage display
In order to obtain specifically Aβ1–42 monomer binding species, a mirror image phage display
with six panning rounds was performed. To reduce binding of phages to larger Aβ1–42 species,
Aβ1–42 oligomers and fibrils were added, starting from round two, as counter-selective agents.
Phages binding to Aβ1–42 oligomers and fibrils were subsequently removed from the solution
leading to an enrichment of phages, which exclusively bind monomeric Aβ1–42.
The target peptide, SEC-derived monomeric, D-enantiomeric, N-terminally biotinylated
Aβ1–42, was immobilized to plates with alternating surface properties. In order to avoid selec-
tion of plastic binding phages, different plastic surfaces were used in each subsequent round
of panning (Nunc 96-well Immobilizer Streptavidin microwell plate, polystyrene (Thermo
Fisher Scientific Inc., Waltham, MA, USA), polypropylene and polycarbonate microwell plates
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96-well (BioTeZ Berlin Buch GmbH, Berlin, Germany)). According to the manufacturer, the
polystyrene plates were pretreated by washing three times with 300 μl of 1x TBS containing
0.05% (v/v) Tween-20 per well. Additionally, in every second round, the surface was blocked
with 150 μl of 1x TBS / 0.1% (v/v) Tween-20 / 1% BSA (w/v) per well with gentle shaking for
one hour at RT prior to the addition of the target peptide to reduce unspecific binding. Thus,
no combination of plate surface and blocking was used twice during the six panning rounds
performed.
One-hundred microliters of a 63 nM solution of target peptide diluted in 1x TBS per well
was immobilized to the well for five minutes at RT, followed by three washing steps with 150 μl
of 1x TBS.
In the first panning round 90 μl of 1x TBS were mixed with 10 μl of the Ph.D.-12 Phage Dis-
play Peptide Library (New England Biolabs GmbH, Frankfurt/M, Germany) and added to the
well for five minutes of incubation at RT. The solution was removed and 100 μl of 10 μM biotin
in 1x TBS / 0.1% (v/v) Tween-20 (TBS-T) were added for five minutes incubation at RT to
reduce streptavidin-binding phages. Subsequently, the well was washed four times with TBS-T.
Elution of bound phages was conducted by adding 100 μl of 0.2 M glycine-HCl (pH 2.2) for
ten minutes at RT. The solution was removed and subsequently added to a fresh reaction tube
with 25 μl of 1 M Tris-HCl (pH 9.1) in order to neutralize the solution. Twenty microliters of
the solution were then used for phage titer determination after elution (output titer). The
remaining volume was used for amplification of the eluted phages.
Determination of the output titer and phage amplification was conducted according to the
distributor´s manual. Shortly, 100 μl of phage dilutions ranging from 10−2 to 10−7 were mixed
with 100 μl E. coli K12 ER2738 cells at an optical density of 0.6. The mixture was plated
together with 800 μl top agar per dilution on LB/Tet/IPTG/XGal Petri dishes (40 x 10 mm) and
incubated overnight at 37°C. The next day, plaques were counted and the titer was determined.
For phage amplification, 20 ml E. coli K12 ER2738 cell solution were grown to an optical
density of 0.1 and incubated with the remaining volume of eluted phages (105 μl) for 4.5 hours
at 37°C and 160 rpm. After incubation, the culture was centrifuged for 20 minutes at 2,300 x g
at 4°C and 1 ml of the supernatant was removed and stored at 4°C. The remaining volume was
precipitated overnight at 4°C with 7 ml PEG-8000 / 2.5 M NaCl. Subsequently, the solution
was centrifuged for 60 minutes at 3,000 x g and 4°C whereupon the supernatant was discarded.
After dissolving the pellet in 1 ml of 1x TBS, the sample was centrifuged for five minutes at
9,300 x g at 4°C. The supernatant was mixed with 200 μl PEG-8000/2.5 M NaCl, followed by
60 minutes incubation on ice and a final centrifugation step for 20 minutes at 16,000 x g and
4°C. The supernatant was removed and the pellet was resuspended in 100 μl of 1x TBS. The
input titer was measured analogically to the output titration with dilutions ranging from 10−8
to 10−13.
While the concentration of the target peptide remained stable, D-enantiomeric Aβ1–42 olig-
omers and high molecular weight (HMW) aggregates/fibrils without an N-terminal biotin tag
were added, starting from panning round two in increasing concentrations (round 2: 1 nM—
round 3: 5 nM—round 4: 10 nM—round 5: 50 nM—round 6: 500 nM) as will be explained
below. Aβ1–42 oligomers and HMW aggregates and fibrils were obtained from SEC and DGC,
respectively, as described above. In order to obtain Aβ1–42 HMW aggregates and fibrils frac-
tions 12, 13 and 14 from the DGC were combined. Due to the addition of the competition step
with Aβ1–42 oligomers and HMW aggregates/, the protocol was adjusted starting from the sec-
ond panning round as follows. The amplified phages from the previous round were diluted to
1x1011 phages in 60 μl of 1x TBS and added to the well previously coated with SEC-derived, D-
enantiomeric, N-terminally biotinylated Aβ1–42 monomers. Twenty microliters of SEC-derived
Aβ1–42 oligomers and 20 μl of DGC-separated Aβ1–42 HMW / fibrils, each diluted in 1x TBS to
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the above mentioned concentration (e.g. for the second panning round 1 nM and 5 nM for
panning round 3), were additionally added to the sample. After five minutes of incubation at
RT, the solution was removed and the procedure went on with the aforementioned biotin com-
petition step. The amount of washing steps increased with every panning round (4–6–8–10–
12–15).
Single phage amplification
Single plaque forming units, each representing phages grown from one single clone, were
picked from the output titer plates from round three to six and added to 5 ml of a E.coli K12
ER2738 culture at an optical density of 0.1 grown in LB/tetracycline medium and were then
amplified for 4.5 h hours at 37°C at 160 rpm. Cultures were centrifuged for 20 minutes at 3,000
x g and 4°C and the supernatant was removed. Two milliliters were used for DNA extraction
and kept at 4°C until usage, one milliliter was aliquoted for single phage ELISA and 0.5 ml were
mixed with 0.5 ml 80% sterile glycerin as backup and stored at -80°C.
Single phage ELISA
The specificity and affinity of single phage clones towards the target peptide and the counterse-
lective agents Aβ1–42 oligomers and HMW aggregates / fibrils was analyzed by ELISA.
320 nM of SEC-derived N-terminally biotinylated D-Aβ1–42 monomers or 320 nM SEC-
derived N-terminally biotinylated D-Aβ1–42 oligomers mixed with DGC-derived N-terminally
biotinylated Aβ1–42 HMW aggregates/fibrils were immobilized in duplicates for each single
phage clone. Therefore, the total amount of Aβ1–42 in each well was 150 ng. Amplified single
phage clones from panning rounds three to six were analyzed. Additionally, the different spe-
cies were immobilized to two wells each in order to check the immobilization efficiency by the
Aβ-specific antibody 6E10 (Beta Amyloid 1–16 (6E10) monoclonal antibody, BioLegend, Ded-
ham, MA, USA). Non-coated wells were used as additional controls for each phage. Addition-
ally, buffer instead of phages was applied as control for cross reactivity of the anti M13:HRP
conjugated antibody to the well surface and the immobilized target in duplicate.
The microtiter plates (Nunc 96-well Immobilizer Streptavidin microwell plate, Thermo
Fisher Scientific Inc., Waltham, MA, USA) were pretreated as recommended by the manufac-
turer. The aforementioned Aβ1–42 species were diluted in 1x TBS to 320 nM each and 100 μl
per well were incubated for 15 minutes at RT with gentle shaking. After washing the wells
twice with 150 μl of 1x TBS and blocking for one hour at RT with 1% (w/v) BSA in TBS-T, the
plates were washed again three times with 150 μl of TBS-T. During the blocking step, the
amplified phages and the buffer control (LB medium) were mixed with 1% (w/v) BSA in
TBS-T in a ratio of 1:1 and incubated on a shaker at RT for 20 minutes. Afterwards 100 μl of
the phage suspensions, the buffer control and the first antibody solution (6E10 1:1,000 in
TBS-T) were given to the wells for one hour with gentle shaking at RT. After washing the plates
for five times with 150 μl of TBS-T, 200 μl of TBS-T were added to each well and the plates
were incubated at RT for another hour.
The supernatant was removed and 100 μl of the antibody dilutions were added to the ade-
quate wells for one hour at RT (mouse anti bacteriophage M13 major coat protein (p8) HRP
conjugated, GE Healthcare Europe GmbH, Freiburg, Germany and goat anti mouse IgG (H+L)
HRP conjugated, Thermo Fisher Scientific Inc., Rockford, IL, USA, respectively). The anti-
M13 antibody was diluted 1:5,000 in TBS-T and the goat anti mouse IgG antibody was diluted
1:1,000 in the same buffer. Subsequently, the plates were washed ten times with 150 μl of
TBS-T and detection was conducted by measuring the conversion of the substrate 3,3',5,5'-tet-
ramethylbenzidine (TMB) by HRP accompanied with a color change. Therefore, 50 μl of a
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TMB solution (one pill TMB was dissolved in 1 ml DMSO and diluted with 9 ml sterile filtered
0.05 M phosphate citrate buffer) was added to each well and color change was stopped by add-
ing 50 μl of 2 M H2SO4 when the solution in the wells started getting turquoise. The absorption
at 450 nm was measured in a microplate reader. After subtraction of the buffer control, the
absorption at 450 nm for the wells coated with Aβ1–42 oligomers and fibrils were normalized to
the Aβ1–42 content of the Aβ1–42 monomer-coated wells as determined by 6E10.
DNA extraction for sequencing
The single stranded phage DNA was purified as described in the NEB phage display manual
(Instruction manual, version 2.7) with the exception that the iodide buffer was exchanged by a
10:1 mixture of 3M sodium acetate (pH 5.2) and TE buffer. Sequencing was conducted by
GATC Biotech AG (Konstanz, Germany).
Transmission electron microscopy (TEM)
In order to analyze which Aβ1–42 species have formed after incubation with the peptide Mosd1,
TEM images were taken. Ten micromolar seedless Aβ1–42 was incubated with or without
10 μMMosd1 for 24 hours at RT. Twenty microliters of each sample were spotted on a for-
mvar/carbon coated copper grid (Plano GmbH, Wetzlar, Germany) for three minutes. After-
wards the solution was detached with filter paper and the grids were washed three times with
20 μl of ddH2O and once with 5 μl 1% aqueous uranyl acetate. Then, 5 μl of the 1% uranyl ace-
tate solution was applied to the grid for one minute for negative staining. The solution was
removed and grids were dried overnight. The samples were analyzed with a Libra 120 transmis-
sion electron microscope (Carl Zeiss AG, Oberkochen, Germany) operating at 120 kV.
Quantitative determination of interference with Aβ1–42 aggregate size
distribution
The density gradient centrifugation method allows matrix-free separation and fractionation of
different Aβ1–42 species according to their sedimentation coefficients which depend on size and
shape.
Aβ1–42 was incubated as mentioned above (250 μl 80 μM seedless Aβ1–42 in 10 mM sodium
phosphate buffer at pH 7.4, 4.5 hours, 600 rpm, RT) in order to gain a mixture of differently
sized species. In order to analyze the influence of Mosd1, coincubation for 40 minutes at RT
with different concentrations of the peptide (0-10-20-40-80 μM) followed.
One-hundred microliters were given on the top of a discontinuous iodixanol gradient and
spun in an ultracentrifuge as described above. Fourteen fractions of 140 μl each were harvested
from top to bottom after centrifugation and the residual pellet (60 μl) was mixed with 60 μl of 6
M guanidine hydrochloride and boiled for ten minutes. This sample represents the 15th frac-
tion. The samples were analyzed by RP-HPLC and Tris-tricine SDS-PAGE followed by silver
staining.
Peptides were quantified via isocratic reversed-phase high performance liquid chromatogra-
phy (RP-HPLC). The column used was a Zorbax SB-300-C8 on a 1260 Infinity system (both
Agilent Technologies Deutschland GmbH, Böblingen, Germany). Twenty microliters of each
sample were injected and run with 1 ml per minute in an aqueous 30% (v/v) acetonitrile / 0.1%
(v/v) trifluoric acid buffer as mobile phase and 80°C column temperature to denature Aβ spe-
cies and separate them from other components, especially iodixanol. The signal was detected at
an absorbance of 214 nm. The data were recorded and peaks were integrated using the Chem-
Station software (Agilent Technologies). In order to calibrate the column, Aβ1–42 solutions of
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known concentration were used to plot peak area versus Aβ1–42 concentration. The plot equa-
tion then allowed calculation of Aβ1–42 concentration within the samples.
Seeding assay (ThT)
In order to analyze the influence of Mosd1 on seeded growth of Aβ1–42, the seeding potential of
fibrillary Aβ1–42 seeds on seedless Aβ1–42 was monitored via Thioflavin T (ThT) fluorescence.
Seedless Aβ1–42 (200 μM in 10 mM sodium phosphate buffer) were incubated at 37°C and
600 rpm for three days in order to gain seeding-competent Aβ1–42 fibrils. The sample was cen-
trifuged at 14,000 x g for 45 minutes at 4°C in order to sediment fibrillary Aβ1–42 content. The
supernatant was removed and the remaining Aβ1–42 fibrils were diluted in 100 μl 10 mM
sodium phosphate buffer. After sonication for two minutes, concentration was determined by
RP-HPLC. Aβ1–42 seeds were incubated with or without a fivefold molar excess of Mosd1 for
additional 24 hours. The mixture of Aβ1–42 seeds and Mosd1 was again sonicated for two min-
utes and added to freshly prepared seedless Aβ1–42 (15 μM) and 20 μMThT. The final concen-
trations were 1.88 μMAβ1–42 seeds and 9.4 μMMosd1. Each sample was added to a 96-well
microtiter plate in triplicate and progression of fluorescence values was monitored over time at
24°C. The experiment was conducted independently for three times.
For each sample an asymmetric five parameter fit was used in order to determine the ampli-
tude of relative fluorescence units and the half-life t1/2. After checking for Gaussian distribution
by D´Agostino-Pearson omnibus normal test, significance was determined by one-way ANOVA.
Cell viability assay (MTT reduction)
PC-12 cells (DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH,
Braunschweig, Germany) were cultured in DMEMmedium supplemented with 10% fetal calf
serum, 1% antibiotics (Penicillin / Streptomycin) (all Sigma-Aldrich Corp., St.Louis, MO,
USA) and 5% horse serum (PAA Laboratories GmbH, Pasching, Germany) on collagen A-
coated (Biochrom GmbH, Berlin, Germany) tissue culture flasks (SPL Life Sciences Co., Korea)
in a humidified incubator with 5% CO2 at 37°C and grown for a maximum of 15 passages.
Medium was changed every two days and cells were passaged, according to their confluence,
every three to five days.
PC-12 cells were seeded in clear, collagen-coated 96-well flat bottommicrowell plates (Life
Technologies Inc., Carlsbad, CA, USA) at a density of 1x104 cells in a volume of 100 μl per well
and incubated for 24 hours. Aβ1–42 / Mosd1 mixtures were incubated as already described in the
above mentioned assay for quantitative determination of interference with Aβ1–42 aggregate size
distribution. Mosd1 concentrations of 0/40/80 μMwere used. From each well that contained
cells 1.25 μl medium were removed and replaced with 1.25 μl of the preparations in order to
gain a final concentration of 1 μMAβ1–42 and 0/1/0.5 μMMosd1 in every well, respectively.
Every approach was tested three times at least in quintuplicates. The plates were incubated for
24 hours in the incubator with 5% CO2 at 37°C. Subsequently, 10 μl of the supernatant were
taken out of every well and 10 μl of MTT reagent (Cell proliferation kit 1, Roche Diagnostics
GmbH, Mannheim, Germany) were added for four hours of incubation in the incubator. After-
wards, 100 μl of solubilization reagent (Roche Diagnostics GmbH, Mannheim, Germany) were
added to all wells and the plate was incubated overnight. The plate was shaken on a table shaker
for five minutes to distribute the purple colored solution equally within each well and absor-
bance was measured at 660 nm and 570 nm with a microplate reader (POLARstar OPTIMA,
BMG Labtech GmbH, Ortenberg, Germany). Reference values at 660 nm were subtracted from
values for formazan absorbance (570 nm). The mean value of cell-free wells was subtracted as
background. The arithmetic mean of all measurements per approach was calculated. Results are
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represented as the percentage of MTT reduction, assuming that the absorbance of control cells
was 100%. Cells treated with 0.1% TritonX-100 in 10 mM sodium phosphate buffer (pH 7.4)
served as control for dead cells. After analysis for Gaussian distribution by Shapiro-Wilk test,
the values were tested for significance using the Mann-Whitney U test.
Western blot to investigate γ-secretase inhibition
Neuro-2a cells (DSMZ, Braunschweig, Germany) and Neuro-2a cells stably transfected with
human APP695 were cultured in DMEM with 10% fetal calf serum and 1x non-essential
amino acids (both Sigma-Aldrich Corp., St.Louis, MO, USA) in tissue culture flasks in a
humidified incubator with 5% CO2 at 37°C. Fifty thousand cells per well were seeded in 500 μl
in a 24 well microwell plate for 24 hours at 37°C and 5% CO2 to assure attachment to the sur-
face. A stock solution of 1 mMMosd1 was prepared in sterile water and the γ-secretase inhibi-
tor DAPT was diluted to 5 mM in DMSO, respectively. The dilutions were spun at 1,000 x g for
one minute prior to use. Then 0/10/100 μMMosd1 and 1 μMDAPT were added to the cell
supernatant and DMSO as well as water were tested as control. The cells were incubated at
37°C and 5% CO2 for 24 hours. The cells were analyzed with a laser scanning microscope LSM
710 (Carl Zeiss AG, Oberkochen, Germany). Afterwards, the cells were washed three times
with 1x PBS and lysed with 60 μl of NP-40 lysis buffer for 15 minutes. The lysates were resus-
pended, transferred to reaction tubes and centrifuged for five minutes at 12,000 x g. After-
wards, the supernatants were transferred to new reaction tubes and protein concentration was
determined via microBCA assay.
For gel electrophoresis the lysates were adjusted to the lowest measured protein concentra-
tion. All samples were mixed with 4x Tris-tricine gel loading buffer (4% SDS (w/v), 12% Glyc-
erin (v/v), 50 mM Tris, 2% β-mercaptoethanol (v/v), 0.01% SERVA BlueG (w/v); pH 6.8) in a
ratio of 1:3 and boiled for ten minutes. Gel electrophoresis was conducted with 10% Tris-tri-
cine gels at a constant voltage of 120 V. The PageRuler prestained protein ladder 10–170 kDa
(Thermo Fisher Scientific, Inc., Rockford, IL, USA) served as marker.
After gel electrophoresis, the proteins were transferred via semi-dry blotting to a PVDF
membrane. Protein transfer took place at 1 A and 25 V for 30 minutes. The membrane was
blocked with 5% non-fat dry milk powder in 1x TBS-T at 4°C overnight with gentle shaking.
Subsequently, the membrane was washed three times with TBS-T at RT and gentle shaking.
The primary antibody for the detection of C-terminal fragment of APP (anti-amyloid precur-
sor protein, C-terminal (751–770) rabbit pAb, Merck KGaA, Darmstadt, Germany) was diluted
1:5,000 in TBS-T. Simultaneously, the anti-β-actin antibody (β-actin (8H10D10) mouse mAb,
Cell Signaling Technology, Inc., Danvers, MA, USA) was diluted 1:1,000 in TBS-T and both
antibodies were given to the membrane, which was incubated overnight at 4°C on a roller
mixer, subsequently. The membrane was washed three times with TBS-T and incubated with
the secondary antibodies goat anti-rabbit IgG:HRP diluted 1:5,000 in TBS-T and goat anti-
mouse IgG:HRP diluted 1:10,000 in TBS-T (both Santa Cruz Biotechnology, Inc., Dallas,
Texas, USA) for three hours at RT on a roller mixer. After three washing steps with TBS-T, the
membrane was incubated with the substrate for enhanced chemoluminescence (SuperSignal
West Dura Chemoluminescent Substrate, Thermo Fisher Scientific, Inc., Rockford, IL, USA)
for five minutes at RT in the dark. The signal was detected with the ChemiDoc MP gel docu-
mentation system (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Results
N-terminally biotinylated, SEC-derived Aβ1–42 monomers were immobilized to streptavidin-
coated microwell plates. To avoid selection of plastic binding ligands, different plastic surfaces
Competitive Mirror Image Phage Display Derived Peptide
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were used in each round. In particular, polystyrene, polypropylene and polycarbonate served
as surface, alternating every round. Additionally, in every second round, the surface was
blocked with BSA. Due to this procedure, six different combinations of blocking and surface
type were used during the panning rounds and not a single combination occurred twice. This
step was important, because only very low concentrations of Aβ1–42 were immobilized in order
to assure its monomeric state. Thus, there was a substantial risk that uncoated surface may
have a strong bias during selection. In the first panning round, only Aβ1–42 monomers were
offered to the naïve library of phages. For the next round, amplified phages from the previous
round were added together with increasing concentrations of non-biotinylated counterselective
Aβ-42 species (SEC-derived oligomers and DGC-derived HMW aggregates and fibrils). After
panning, a biotin competition step was conducted to remove phages that compete with biotin.
Afterwards the well was washed every round with increasing rigor and still bound phages were
eluted and amplified.
We verified the state of all used Aβ conformers by DGC followed by Tris-tricine-SDS-PAGE
and silver staining. SEC-derived Aβ1–42 monomers, SEC-derived oligomers, and fibrillary Aβ1–42
were analyzed. As shown in Fig 1, prepared monomers are indeed free of any aggregates, as only
the most upper fractions 1 and 2 of the DGC gradient contained Aβ. Oligomers can be found pre-
dominantly in fractions 4 to 6, and in smaller amounts also in neighboring fractions. Fibrils can
be found in the extreme high molecular weight fractions, but obviously, during the DGC run, a
substantial fraction of monomers dissociated from them and can be found in fractions 1 and 2.
Single phage clones from round three to six were amplified and sequenced. Sixteen
sequences occurred more than once and were therefore tested for binding to monomeric Aβ1–
42, Aβ1–42 oligomers and HMW aggregates / fibrils as well as non-coated wells in a single phage
ELISA. Additionally, several clones with uniquely occurring sequences and four clones from a
previously conducted mirror image phage display were tested. This former mirror image phage
display was conducted with almost identical conditions. The experimental setup differed only
in two details. Firstly, the counterselective Aβ1–42 HMW aggregates and fibrils were derived
from an iodixanol gradient with different iodixanol concentrations (30–24–18–12–6 and 3%
iodixanol instead of 50–40–30–20–10 and 5%). Secondly, the neutralization of the eluate took
place in the same well as the elution step.
Fig 2 shows the immobilization efficiency of different Aβ1–42 species detected by Aβ1–42 spe-
cific antibody 6E10. On all plates used for single phage ELISA, Aβ1–42 monomers and oligo-
mers/fibrils were immobilized in an amount which allowed normalization of the Aβ1–42
oligomer/fibril content to the content of Aβ1–42 in Aβ1–42 monomer-coated wells as determined
by 6E10. As shown in Fig 3, the competitive mirror image phage display selection indeed
yielded phages that display peptides that specifically bind to Aβ1–42 monomers as demon-
strated by the strong binding to Aβ1–42 monomer coated wells and notably less binding to wells
coated with Aβ1–42 oligomers and HMW aggregates or fibrils. We picked the clone with the
highest signal intensity for monomeric Aβ1–42, but also the highest specificity for monomeric
Aβ1–42 as deduced from the high ratio of binding to Aβ1–42 monomers and binding to oligo-
meric and fibrillary Aβ1–42. The amino acid sequence of the chosen clone 5.60 was YSYLT-
SYHMVWR. The corresponding D-enantiomeric peptide, named Mosd1 (monomer specific
d-peptide 1), was synthesized from purely D-amino acids with its C-terminus amidated, and
was further characterized.
In order to obtain information on how Mosd1 changes Aβ1–42 aggregation, TEM pictures
were taken after 24 hours incubation of Aβ1–42 with and without an equimolar ratio of Mosd1.
The Aβ1–42 sample without Mosd1 contained a mesh of fibrils (Fig 4A). Additionally, Aβ oligo-
mers and large aggregates (dot-like structures) were present, displaying a broad range of aggre-
gated Aβ1–42 species. In the sample with Aβ1–42 and Mosd1 neither fibrils nor oligomers were
Competitive Mirror Image Phage Display Derived Peptide
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observed. Instead, amorphous, unstructured aggregates were the major species found on the
grid (Fig 4B).
After incubation of 80 μMAβ1–42 followed by coincubation with different concentrations of
Mosd1 (0/10/20/40/80 μM), samples were loaded on a discontinuous iodixanol gradient and
Fig 1. Silver stained Tris-Tricine-SDS-PAGE of different Aβ1–42 species. The Aβ1–42 species used for panning and counter selection during mirror image
phage display were analyzed via DGC followed by Tris-Tricine-SDS-PAGE and silver staining. The SEC peak corresponding with Aβ1–42 monomers (A)
presents Aβ1–42 content only in fractions 1 to 2 of a DGC gradient and therefore represents exclusively monomeric Aβ1–42. The SEC peak corresponding with
Aβ1–42 oligomers (B) presents mainly Aβ1–42 in fractions 4 to 6, which is in accordance with oligomeric Aβ1–42 species. The preparation of fibrillary Aβ1–42
resulted in monomeric and fibrillary Aβ1–42 content as seen in fractions 1 to 2 and 13 to 14 (C). Using only the pooled fractions 12 to 14 ensured that no
monomeric Aβ1–42 species were used as counterselective agent.
doi:10.1371/journal.pone.0147470.g001
Fig 2. Single phage ELISA—immobilization control. The immobilization efficiency of different Aβ1–42 species was analyzed by the binding affinity of Aβ1–
42 specific antibody 6E10 to immobilized Aβ1–42 on each plate used for single phage ELISA. The Aβ1–42 specific antibody 6E10 was added to wells coated
with 150 ng Aβ1–42 monomers (red) or 150 ng Aβ1–42 oligomers and fibrils (1:1; green) or to wells only coated with streptavidin (blue). Transformation of
substrate by the secondary antibody-conjugated HRP was measured at 450 nm.
doi:10.1371/journal.pone.0147470.g002
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centrifuged. Fifteen fractions were harvested from top to bottom, applied to Tris-tricine-
SDS-PAGE and silver stained. With this experiment we were able to show that Mosd1 abol-
ishes different Aβ1–42 species from the sample, which contains Aβ1–42 species of different size,
ranging from monomers to fibrils and HMW aggregates.
The distribution of 80 μMAβ1–42, incubated for 4.5 hours without addition of Mosd1,
showed a broad range of species distributed from fraction 1 to 12, representing monomers,
small and large oligomers, protofibrils, fibrils and HMW aggregates (Fig 5A) [37]. The amount
of Aβ1–42 as estimated from silver staining decreased with the fraction number, indicating
substantial amounts of Aβ1–42 in form of monomers and small oligomers. The most toxic olig-
omers can be expected in fractions four to six [38]. The addition of Mosd1 shifted the distribu-
tion of Aβ1–42 towards large aggregates (Fig 5B–5E). This aggregates are suspected to be non-
toxic [39]. The Aβ1–42 contents in fractions one to ten were decreased with increasing Mosd1
concentrations. We therefore conclude that Mosd1 decreased the amount of toxic Aβ1–42 oligo-
mers and shifted the distribution equilibrium towards non-toxic aggregates in a concentration
dependent manner.
Silver staining does not allow a quantitative determination of the detected species. In order
to gain quantitative information about Aβ1–42 concentrations in every fraction, samples of each
fraction were applied to RP-HPLC chromatography and analyzed for their Aβ1–42 contents, as
described before [40]. The QIAD (quantitative determination of interference with Aβ1–42
aggregate size distribution) assay fully confirmed the above described behavior of Mosd1 and
Fig 3. Single phage ELISA. The relative binding affinity of single phage clones frommirror image phage display (clone numbers 6.xx) and a previously
conducted mirror image phage display (clone numbers 5.xx) to SEC-derived biotinylated Aβ1–42 monomers, oligomers and fibrils as well as the non-coated
wells was analyzed. The M13 phage-specific antibody was used for detection. Transformation of substrate by the antibody-conjugated HRP was measured
at 450 nm. Amplified single phage clones were added to wells coated with 150 ng Aβ1–42 monomers (red) or 150 ng Aβ1–42 oligomers and fibrils (1:1; green)
or to wells only coated with streptavidin (blue). Cross reactivity of the M13 phage-specific antibody was tested in an approach without addition of phages.
After background subtraction of the anti M13 antibody values, the values for phage to Aβ1–42 oligomer/fibril binding were normalized to the values of phage to
Aβ1–42 monomer binding according to the outcome of coating efficiency controls with the Aβ specific antibody 6E10.
doi:10.1371/journal.pone.0147470.g003
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demonstrates that Aβ1–42 oligomer elimination by Mosd1 is concentration dependent (Fig 6).
Most importantly, Mosd1 is able to almost completely eliminate Aβ1–42 oligomers.
A characteristic property of fibrillar Aβ to is its ability to act as a seed for conversion of
monomeric Aβ into fibrillar Aβ assemblies. We therefore analyzed the impact of Mosd1 on
Fig 4. Transmission electronmicroscopy. After incubation of 10 μM pretreated Aβ1–42 without (left picture) and with 10 μMMosd1 (right picture) for 24
hours at room temperature, samples were spotted onto a formvar/carbon coated copper grid and stained with 1% aqueous uranyl acetate. Samples were
analyzed with a Libra 120 TEM operating at 120 kV. Scale bar presents 0.25 μm.
doi:10.1371/journal.pone.0147470.g004
Fig 5. Qualitative Aβ1–42 distribution alteration. Silver staining of SDS gels after incubation of 80 μMAβ1–42 for 4.5 hours at RT and 600 rpm and additional
coincubation for 40 minutes with 0 (A) / 10 (B) / 20 (C) / 40 (D) / 80 μM (E) Mosd1 followed by density gradient centrifugation for three hours at 4°C at 259,000
x g. The bands display the signal for Aβ1–42 (4.5 kDa).
doi:10.1371/journal.pone.0147470.g005
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fibril seeded fibrillation of Aβ1–42 using the Thioflavin T (ThT) assay (Fig 7). Fibrillar Aβ1–42
seeds were grown and afterwards incubated with or without Mosd1. ThT was added and the
mixture was added to freshly prepared seedless Aβ1–42. The progression of ThT fluorescence
was monitored over time. Compared to freshly prepared seedless Aβ1–42 (t1/2 = 19.69 h), addi-
tion of fibrillary Aβ1–42 seeds significantly reduced the time needed to increase fibrillar content
(t1/2 = 0.57 h). When fibrillary Aβ1–42 seeds were coincubated with Mosd1 prior to addition of
freshly prepared seedless Aβ1–42, the time for the increase of fibrillary content was significantly
reduced as well, yet the time for the increase was significantly longer (t1/2 = 3.36 h) compared
to the sample without Mosd1 (Fig 7A). Furthermore, the amount of fibrillar Aβ1–42 content in
the samples, displayed by the amplitude of relative fluorescence units (Fig 7B), did differ signif-
icantly between seedless Aβ1–42 (set to 100% RFU) and seedless Aβ1–42 incubated with fibrillary
Aβ1–42 seeds (84%) as well as between seedless Aβ1–42 and fibrillary Aβ1–42 seeds coincubated
with Mosd1 (74%).
In order to confirm that Mosd1 yields Aβ1–42 species that are not toxic to cells and Mosd1
can indeed abolish the cytotoxic effect of Aβ1–42 and rescue cell viability, an MTT assay was
performed (Fig 8). PC-12 cells were incubated with Aβ1–42 with or without different concentra-
tions of Mosd1, derived from the same incubation method as mentioned above. Mosd1 without
Aβ1–42 was tested to ensure that Mosd1 itself is not toxic to the cells. TritonX-100 was used as
Fig 6. Quantitative concentration determination (RP-HPLC) of Aβ1–42 distribution. Concentrations of Aβ1–42 in each DGC fraction were determined
quantitatively via RP-HPLC. Samples were loaded to a Zorbax 300SB-C8 column connected to a 1260 Infinity HPLC system. Separation of the samples was
achieved by elevated column temperature (80°C) and an isocratic mobile phase of 30% acetonitrile/0.1% TFA in water. The averaged concentration of Aβ1–
42 from three independent experiments (with standard deviation) is plotted against the obtained fractions F1 to F15 of different incubation approaches of Aβ1–
42 without or with Mosd1. Shown in red are the concentrations of fractions from 80 μMAβ1–42 incubated without Mosd1. The following columns represent the
Aβ1–42 concentrations in the fractions from 80 μMAβ1–42 samples coincubated with increasing concentrations of Mosd1 (10 μM = light blue; 20 μM = dark
blue; 40 μM = light green; 80 μM = dark green).
doi:10.1371/journal.pone.0147470.g006
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a control for cell death. Untreated cells were set 100% viable and all other values were normal-
ized to this value. Incubation with 0.1% TritonX-100 resulted in 1.6% viable cells. The Aβ1–42
composition led to a significantly decreased cell viability of 45% and was therefore proven to be
toxic. Mosd1 in a concentration of 1 μM did not alter MTT reduction in this assay and showed
no toxic effect in PC-12 cells. When coincubated with Mosd1, the toxic effect of Aβ1–42 was sig-
nificantly decreased with increasing concentrations of Mosd1. In an equimolar ratio, 86% of
the cells stayed viable and with half the concentration of Mosd1 still 66% of the cells were via-
ble. Mosd1 is therefore able to rescue PC-12 cells from Aβ1–42 induced toxicity.
Neuro-2a cells, stably transfected with human APP695, develop a pathologic phenotype
when compared with wild type Neuro-2a cells. Wild type Neuro-2a cells accumulate and grow
protrusions between each other and appear polygonal, whereas Neuro-2a cells, which are stably
transfected with human APP, appear isolated, spindle shaped and show less protrusions and
cell contacts (Figs 9 and 10). Applied to wild type Neuro-2a cells, Mosd1 did not alter their
physiological phenotype. The cells clotted and developed protrusions and appeared polygonal
(Fig 9). Added to hAPP695-transfected Neuro-2a cells, Mosd1 compensated the pathological
phenotype (Fig 10). The cells developed connections and protrusions, grew denser and did par-
tially clot, resembling the phenotype of wild type Neuro-2a cells. This effect is dose dependent,
Fig 7. Reduction of seeded Aβ1–42 growth and fibrillar Aβ1–42 content. Seedless Aβ1–42 was incubated alone (black) or together with fibrillary Aβ1–42
seeds previously incubated with (green) or without (red) a fivefold molar excess of Mosd1. ThT (20 μM) was added to each sample in order to measure
fibrillar content. The data were fitted with an asymmetric five parameter fit. The (A) amplitude of relative fluorescence (RFU) of fibrillated seedless Aβ1–42
served as 100% to which the other values were normalized. The (B) half-life (t1/2), displaying the point in time, when half of the maximum ThT signal (i.e.
fibrillary content) was reached. Statistical significance was determined by one-way ANOVA. Error bars display SEM. ns: p > 0.05; *: p 0.05; **: p 0.01;
***: p 0.001.
doi:10.1371/journal.pone.0147470.g007
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since higher concentrations of Mosd1 (10 and 100 μM) increased the development of cellular
connections.
Because Mosd1 binds Aβ1–42 monomers, it might also bind to the respective part of APP
and influence its cleavage by γ-secretase. In order to investigate this potential side activity, we
analyzed whether Mosd1 influences γ-secretase activity with APP as a substrate. Neuro-2a
cells, stably transfected with the gene coding for human APP695 were incubated with 10 and
100 μMMosd1, respectively. The cells were lysed, lysates were separated by SDS-PAGE, blotted
and the APP C-terminal fragment β (APP CTFβ) was detected by enhanced chemolumines-
cence. Both concentrations of Mosd1 showed no signs of γ-secretase activity inhibition, i.e. the
γ-secretase substrate APP CTFβ was not accumulated as it is the case for the treatment with
the γ-secretase inhibitor DAPT (Fig 11) [41, 42].
Discussion
The competitive mirror image phage display yielded Aβ1–42 monomer
specific ligands
Our competitive mirror image phage display led to single phage clones that preferentially
bind to monomeric Aβ1–42. Sequencing of single phage clones revealed several consensus
sequences which occurred multiply. Additionally, ELISA results showed an overall specificity
Fig 8. Effect of Aβ1–42 and Mosd1 on cell viability. Aβ1–42 and Mosd1 were tested for their influence on PC-12 cell viability by MTT reduction assay. Cell
viability (in percent) is plotted against different treatment conditions. Adherently grown PC-12 cells were incubated 24 hours with medium (black) or 0.1%
TritonX-100 (yellow) as controls for viable cells and cytotoxicity, respectively. Additionally, cells incubated for 24 hours with 1 μMAβ1–42 (red), Aβ1–42
+ Mosd1 1:1 (light blue) and 1:0.5 (dark blue), respectively. The green bar corresponds to cells incubated with 1 μMMosd1 for 24 hours. Viability was
analyzed by subsequent incubation with MTT substrate for four hours. After solubilization, absorbance was measured at 570 nm. The averages and standard
deviations of absorbance values from five independently performed experiments were calculated and normalized to untreated cells (medium). Statistical
significance was tested with Mann-Whitney U test. ***: p 0.001.
doi:10.1371/journal.pone.0147470.g008
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of most single phage clones for monomeric Aβ1–42 compared to Aβ1–42 oligomers and fibrils
and non-coated wells. Several single phage clones exhibited a very strong difference in binding
affinities between monomeric and aggregated Aβ1–42 and also the non-coated surface. We
picked the most promising clone and investigated the respective D-peptide Mosd1 for further
analysis.
Mosd1 modulates Aβ1–42 aggregation
Via TEM and quantitative determination of Aβ1–42 aggregate distribution, we were able to
show that coincubation of Aβ1–42 with Mosd1 leads to an altered aggregation pathway of Aβ1–
42. While incubation of Aβ1–42 alone for 24 hours led to oligomers and fibrillar structures, coin-
cubation with Mosd1 led to large amorphous aggregates that were shown to be non-toxic [30,
39, 40]. By combining these results with the experiment regarding interference of Mosd1 with
Aβ1–42 aggregate size distribution mentioned above, we suggest the following mode of action.
Mosd1 stabilizes Aβ1–42 monomers and thereby modulates the dynamic equilibrium of Aβ1–42
species. Toxic Aβ1–42 oligomers are decomposed and the resulting Aβ1–42 species being precipi-
tated and converted into amorphous non-toxic aggregates instead of fibrils. According to Ladi-
wala et al., Mosd1 can be sorted into class I molecules, which convert soluble Aβ oligomers
into large, non-toxic conformers [43]. In addition, Mosd1 with 33% residues being aromatic
shares the overall aromatic features of compounds, which belong to this class. Indeed, also
polyphenols like resveratrol and derivatives or polyphenolic flavones like kaempferol-3-O-
rhamnoside are able to cause the development of large, non-toxic, off-pathway Aβ aggregates
Fig 9. Effect of Mosd1 on Neuro-2a cells.Overview and detailed pictures of wild type Neuro-2a cells are shown. Neuro-2a cells were treated with 0, 10 and
100 μM of Mosd1, respectively. The left panel shows untreated wild type Neuro-2a cells. In the middle and right panel, incubation of wild type Neuro-2a cells
with 10 μMMosd1 and 100 μMMosd1 are shown. Cell viability and morphology were analyzed with a LSM 710 laser scanning microscope. Scale bars
equate 50 μm.
doi:10.1371/journal.pone.0147470.g009
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as shown in TEM, AFM and SDS-PAGE studies by several research groups [44, 45]. Addition-
ally, Mosd1 is able to decelerate Aβ1–42 aggregation. Therefore, Mosd1 is able to reduce the
impact of already formed Aβ1–42 seeds on monomeric Aβ1–42 and their conversion into toxic
aggregates as shown by Seeding ThT Assay.
According to cell culture experiments, aggregates generated by coincubation of Aβ1–42 with
Mosd1 are not toxic to PC-12 cells, whereas, the mixture of Aβ1–42 species not treated with
Mosd1 showed significant cellular toxicity. Other compounds, which consist of aromates or
include aromatic side chains, were also reported to reduce Aβ induced cell toxicity [43, 45, 46].
This might be contributed to the binding to Aβ1–42 monomers and prevention of their aggrega-
tion as well as to the conversion of toxic oligomeric Aβ1–42 species into large non-toxic species
as shown in the latter experiments.
Additionally, we were able to show that human APP695 transfected Neuro-2a cells, treated
with Mosd1, appear healthier compared to untreated cells, which develop a pathological phe-
notype. Mosd1 is able to reverse the effects of human APP695 expression and its cleavage prod-
ucts like reduced cell contacts and a lack of cellular protrusions.
Despite the fact that Mosd1 reduces Aβ1–42 toxicity by modulating the equilibrium of Aβ1–
42 species, it needs to be assured, that the compound is safe and does not interfere with related
but physiological relevant pathways. For example, γ-secretases are involved in the cleavage of
APP, leading subsequently to Aβ. Moreover, γ-secretases are also involved in cleavage of trans-
membrane Notch and therefore interfere with Notch signaling pathways. Alterations within
the Notch pathway can lead to severe side effects [47, 48]. According to our results Mosd1 has
no effect on γ-secretase activity.
Fig 10. Effect of Mosd1 on Neuro-2a cells stably transfected with human APP695.Overview and
detailed pictures of Neuro-2a cells, stably transfected with human APP695, are shown. Cells were treated
with 0, 10 and 100 μM of Mosd1, respectively. The left panel shows untreated hAPP695-transfected Neuro-
2a cells. In the middle and right panel, incubation of hAPP695-transfected Neuro-2a cells with 10 μMMosd1
and 100 μMMosd1 are shown. Cell viability and morphology were analyzed with a LSM 710 laser scanning
microscope. Scale bars equate 50 μm.
doi:10.1371/journal.pone.0147470.g010
Competitive Mirror Image Phage Display Derived Peptide
PLOS ONE | DOI:10.1371/journal.pone.0147470 February 3, 2016 17 / 22
Given the usefulness of mirror image phage display to obtain stable D-peptides for syntheti-
cally available targets, we wonder why there have been only a limited number of reports
describing such approaches [49–52] and those described in reviews [26, 34, 53].
Conclusion
Taken together, we have established a novel competitive mirror image phage display for the
selection of D-enantiomeric peptides, which bind specifically to monomeric Aβ1–42. Using
non-biotinylated SEC-derived oligomers and DGC-derived HMW aggregates and fibrils of
Aβ1–42 as counterselective agents, we were able to enrich phages, which bind specifically to the
immobilized biotinylated monomeric Aβ1–42.
One of our selected D-enantiomeric peptides, Mosd1, shows promising characteristics in
several in vitro experiments. This leads to the assumption that Mosd1 is able to stabilize Aβ1–42
monomers, interferes with seeded growth and modulates Aβ1–42 aggregation towards non-
toxic, amorphous aggregates and therefore rescues cells from Aβ1–42 derived toxicity and
reverses pathological phenotypes from hAPP-transfected neuronal cells.
Mosd1 also does not affect γ-secretase function which makes it safer and more precise than
γ-secretase modulating compounds. Its small size should facilitate blood-brain-barrier transfer
and the D-enantiomeric conformation enables high proteolytic stability. Further investigations
Fig 11. Analysis of potential γ-secretase activity alterations by Mosd1.Detection of CTFβ and β-actin by
enhanced chemoluminescence on aWestern blot of lysed human APP695-transfected Neuro-2a cells.
Human APP695-transfected Neuro-2a cells were grown in 24-well plates for 24 hours. Cells were incubated
with DMSO (lane 1), DAPT (lane 2), 10 μMMosd1 (lane 3) or 100 μMMosd1 (lane 4) for additional 24 hours.
The cells were harvested, lysed and proteins were separated by Tris-tricine SDS-PAGE. Proteins were
blotted on a PVDFmembrane and detected with an anti-APP-CTF antibody as well as an anti-β-actin
antibody. Binding of HRP conjugated secondary antibodies was detected by transformation of enhanced
chemoluminescence (ECL) substrate by HRP.
doi:10.1371/journal.pone.0147470.g011
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including affinity studies and epitope mapping should provide more information about the
mechanism howMosd1 modulates Aβ1–42.
We were able to show that a competitive mirror image phage display is a straightforward
method to select compounds, which are Aβ1–42 monomer specific and able to modulate Aβ1–42
aggregation towards non-toxic species and therefore exhibit high therapeutic potential.
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